AMVUTTRA™

AMVUTTRA™ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Administration and Dosage:

AMVUTTRA™ is dosed 4 times per year via subcutaneous injection

Common Side Effects:

The most common adverse reactions that occurred in patients treated with AMVUTTRA were arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

More Information:

Please see full Prescribing Information including Patient Information.

Ready to Schedule an Appointment?

Please CLICK HERE to get started.

Indication:

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Follow Us On Instagram